Using artificial intelligence-powered software for screening electrocardiograms (ECGs) could deliver results more quickly and allow treatment to be started earlier, according to a new study
Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the
Screening people in primary care with a wearable heart monitor developed by iRhythm was able to increase diagnoses of atrial fibrillation (AFib) by 52%, although it did not result in a redu
Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but th
Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
